• Japanese
  • Korean
  • Chinese
Cover Image

Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth

Abstract

Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth", which provides insights into the India anti-diabetes market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. Insights into the diabetes epidemiology, cost of therapy, research and development pipeline and the promising molecules which are anticipated to be launched by 2018 are discussed in the report. The report provides an in-depth analysis type 1 and type 2 diabetes. The report provides an in-depth analysis on oral anti-diabetics agents, insulin products and drivers and barriers that could significantly impact the overall anti-diabetes market during the forecast period. Additionally, it explores the competitive landscape, including benchmarking the top companies in the market and the key issues and trends that are likely to have an impact on the Indian diabetes market during the forecast period. Finally, a key trend analysis for mergers and acquisitions and licensing agreements involving diabetes therapies is also discussed in the report.

GBI Research's analysis revealed that the overall anti-diabetes market in India was worth $680.3m in 2011 and is projected to grow at a CAGR of 11.3% between 2011 and 2018 to reach $1,446m in 2018. High and growing diabetes population in the country, rising obese and geriatric population, and rapid market adoption of drugs from the classes such as Dipeptidyl Peptidase 4 (DPP-4) inhibitors, Glucagon-Like Peptide (GLP)-1, Sodium-Glucose Transport Proteins (SGLT-1) and others would drive the anti-diabetes market in the forecast period. The R&D product pipeline for DM, dominated by OAD agents, consists of around 200 molecules at various stages of clinical development. Paradoxically, type 2 diabetes therapeutics market, crowded with many generics and branded generics drug products, is being seen as a significant growth opportunity for new patent protected products owing to high prevalence, progressive nature of the disease and considerably high unmet needs. Of overall R&D pipeline molecules, more than 90% are being studied for the treatment of type 2 DM.

Many multinational companies, such as Novartis, Eli Lilly, are engaged in setting up strategic marketing and distribution agreements with domestic players to improve their patient base and so the market share. Growing at a double digit year on year growth rate, the Indian anti-diabetics market is very promising and offers lucrative opportunities to both domestic as well as foreign pharmaceutical players.

Scope

  • Data and analysis on the Indian diabetes therapeutics market
  • Annualized market data for the diabetes therapeutics market from 2004 to 2011, with forecasts to 2018 for type 1 and type 2 diabetes.
  • Epidemiological data on type 1 and type 2 diabetes along with market size, annual cost of therapy, unmet needs and economic burden of diabetes.
  • Key drivers and restraints that have had a significant impact on the market.
  • Major trends and issues which are likely to have a significant impact on overall diabetes therapeutics market in India
  • Competitive landscape of the diabetes therapeutics market including top companies benchmarking. The key companies studied in this report are Novo Nordisk, Sanofi, Novartis, Eli Lilly, Merck, Abbott, USV, Sun Pharma, Biocon and Wockhardt.
  • Key M&A activities and licensing agreements, major deals that took place in last four years in Indian diabetes therapeutics market.

Reasons to buy

  • Align their product portfolio to the markets with high growth potential.
  • Build effective strategies to launch their pipeline products by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of top competitors.
  • Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential.
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

TOC

1 Table of Contents

1 Table of Contents 6

  • 1.1 List of Tables 10
  • 1.2 List of Figures 10

2 Diabetes Therapeutics Market in India to 2018 - Overview 11

  • 2.1 Diabetes Mellitus - A Global Overview 11

3 Diabetes Therapeutics Market in India - Introduction 12

  • 3.1 Type 1 Diabetes Mellitus 12
    • 3.1.1 People at Risk 12
    • 3.1.2 Risk Factors for Type 1 Diabetes 12
    • 3.1.3 Symptoms 12
  • 3.2 Type 2 Diabetes Mellitus 13
    • 3.2.1 People at Risk 13
    • 3.2.2 Risk Factors for Type 2 Diabetes 13
    • 3.2.3 Symptoms 13
  • 3.3 Gestational Diabetes Mellitus 13
    • 3.3.1 Risk Factors for Gestational Diabetes Mellitus 13
  • 3.4 Diagnosis of Diabetes Mellitus 14
  • 3.5 Diabetes Treatment Guidelines - India 15
    • 3.5.1 Introduction 15
    • 3.5.2 Prevention of Diabetes 15
    • 3.5.3 Diabetes Treatment 15
  • 3.6 Diabetes Mellitus Complications 16

4 Diabetes Therapeutics Market in India to 2018 - Major Drug Classes 17

  • 4.1 Sulfonylureas 17
    • 4.1.1 Introduction 17
    • 4.1.2 Mechanism of Action 17
    • 4.1.3 Major Drugs 18
  • 4.2 Thiazolidinediones 18
    • 4.2.1 Introduction 18
    • 4.2.2 Mechanism of Action 18
    • 4.2.3 Example 18
  • 4.3 Biguanides 19
    • 4.3.1 Introduction 19
    • 4.3.2 Mechanism of Action 19
    • 4.3.3 Drug Products 19
  • 4.4 Meglitinides 20
    • 4.4.1 Introduction 20
    • 4.4.2 Mechanism of Action 20
    • 4.4.3 Major Drugs 20
  • 4.5 Alpha-Glucosidase Inhibitors 21
    • 4.5.1 Introduction 21
    • 4.5.2 Mechanism of Action 21
    • 4.5.3 Major Drugs 21
  • 4.6 Glucagon-Like Peptide Analogs and Agonists 22
    • 4.6.1 Description 22
    • 4.6.2 Mechanism of Action 22
    • 4.6.3 Major Drugs 22
  • 4.7 Dipeptidyl Peptidase-4 Inhibitors 22
    • 4.7.1 Description 22
    • 4.7.2 Mechanism of Action 22
    • 4.7.3 Major Drugs 23
  • 4.8 Glucagon-Like Peptide-1 Analogs vs. Dipeptidyl Peptidase-4 Inhibitors 23
  • 4.9 Insulin Preparations 23
    • 4.9.1 Introduction 23
    • 4.9.2 Types of Insulin 23

5 Diabetes Therapeutics Market in India to 2018 - Epidemiology 25

  • 5.1 Introduction 25
  • 5.2 Diabetes Population in India 27
  • 5.3 Diagnosed Population 29
  • 5.4 Treated Population 29

6 Diabetes Therapeutics Market in India to 2018 - Revenue Forecasts 30

  • 6.1 Introduction 30
    • 6.1.1 Oral Anti-Diabetics Market 31
    • 6.1.2 Insulin Market 31
  • 6.2 Annual Cost of Therapy 32

7 Diabetes Therapeutics Market in India to 2018 - Economic Burden of Diabetes in India 33

  • 7.1 Economic Burden of Diabetes in India 33
    • 7.1.1 Introduction 33
    • 7.1.2 Healthcare Expenditure on Diabetes in India 33
  • 7.2 Collaborative Efforts Necessary to Address the Rising Burden of Diabetes 34

8 Diabetes Therapeutics Market in India to 2018 - Drivers and Barriers 35

  • 8.1 Market Drivers 35
    • 8.1.1 Aging Population, Sedentary Lifestyle and Unhealthy Diet is Driving the Diabetic Population in India 35
    • 8.1.2 Promising Molecules Offering Improved Clinical Outcomes Could Increase Patient Base on Therapy 35
    • 8.1.3 Untapped Areas Offer Promising Opportunities to Pharmaceutical Companies 36
  • 8.2 Market Barriers 36
    • 8.2.1 Low Diagnosis and Prescription Rate 36
    • 8.2.2 Highly Competitive Market Driven by Generics and Branded Generics Increases Pricing Pressure 36
    • 8.2.3 High Out-of-Pocket and Low Healthcare Expenditure on Diabetes 37

9 Diabetes Therapeutics Market in India to 2018 - Unmet Needs 38

  • 9.1 Introduction 38
  • 9.2 High Cost of Therapy and Drug Safety Issues Affect Patient Compliance 38
  • 9.3 Unmet Need Creates Opportunities for Pharmaceutical Companies 38

10 Diabetes Therapeutics Market in India to 2018 - Product Pipeline Analysis 39

  • 10.1 Profiles of Promising Molecules in R&D Development 40
    • 10.1.1 IN-105 (Oral Insulin) 40
    • 10.1.2 NN9068/IDegLira/degludec +/- liraglutide 40
    • 10.1.3 Dapagliflozin 41
    • 10.1.4 Canagliflozin/TA-7284 42
    • 10.1.5 Lixisenatide 42
    • 10.1.6 Alogliptin 42

11 Diabetes Therapeutics Market in India to 2018 - Case Studies 43

  • 11.1 Avandia Fallout Impact 43
    • 11.1.1 Introduction 43
    • 11.1.2 Cardiovascular Safety Issues 43
    • 11.1.3 Impact on GlaxoSmithKline 43
    • 11.1.4 Impact on Drug Approvals 43
  • 11.2 Januvia from Merck an Example that Patented Products can succeed in India 44
    • 11.2.1 Introduction 44
    • 11.2.2 Improved Pharmacological Effect of DPP-4 Inhibitors Helped Rapid Adoption 44
    • 11.2.3 Januvia and Janumet a New Growth Engine for Merck 44
    • 11.2.4 Robust Approach Needed to Market a New Drug Product in India 44
    • 11.2.5 Excellent Commercialization Strategy 45
    • 11.2.6 Conclusion 45

12 Diabetes Therapeutics Market in India to 2018 - Major Trends and Issues 46

  • 12.1 Biguanides Class is dominated by Generics 46
  • 12.2 Evolving Oral Hypoglycemic Agents Resulting in Smaller Market Share Sulfonylureas 46
  • 12.3 Increasing Competition in Dipeptidyl Peptidase-4 Inhibitor Class 46
    • 12.3.1 DPP-4 Inhibitors Likely to Face Potential Competition from GLP-1 Agonists 46
  • 12.4 Thiazolidinedione Class to Face Impact of Avandia Fallout 47
  • 12.5 GLP-1 Agonists Must Demonstrate Better Safety and Efficacy Profiles to Compete with other Oral Hypoglycemic Class 47
  • 12.6 Fierce Competition in the Insulin Market is Likely to Increase 48
  • 12.7 Is Oral Insulin the Next Big Thing in the Insulin Market? 48
    • 12.7.1 Introduction 48
    • 12.7.2 Oral Insulin Not for All 48
    • 12.7.3 Challenges to Overcome 48
    • 12.7.4 Would it lead to Market Cannibalization? 49
  • 12.8 India Diabetes Market: Setting up for the Biosimilars? 49
    • 12.8.1 Introduction 49
    • 12.8.2 Insulin Biosimilar Market 49
    • 12.8.3 Sanofi's Lantus a Lucrative Target 49
    • 12.8.4 Need for Dose Adjustments would Discourage Uptake of Biosimilars 50
    • 12.8.5 Price Discounts Alone would be Insufficient 50
    • 12.8.6 Strong Brand Promotion would be Necessary for Insulin Biosimilars 50
    • 12.8.7 Collaborations and Licensing Agreements are Key 50
    • 12.8.8 Conclusion 51
  • 12.9 Sodium Glucose Co-Transporter2 Inhibitors: A New Class to Hit the Market? 51
  • 12.10 Glucokinase Activators 51
  • 12.11 Stem Cell Therapies: The Next Prospective Therapy for Diabetes? 52
    • 12.11.1 Introduction 52
    • 12.11.2 What are Stem Cells? 52
    • 12.11.3 Stem Cell Therapies and Diabetes 52
    • 12.11.4 Conclusion 52
  • 12.12 Price Discounts a Decisive Factor in the Increasingly Competitive Anti-Diabetes Market 53
  • 12.13 Favorable Government Polices to Promote Generics 53
  • 12.14 Strategic Consolidation to Increase Growth Prospects 54
    • 12.14.1 Introduction 54
    • 12.14.2 Shift of Focus towards Rural and Class II-IV Towns 54

13 Diabetes Therapeutics Market in India to 2018 - Competitive Landscape 55

  • 13.1 Novartis India Limited (Novartis India) 55
  • 13.2 Novo Nordisk India Private Limited (Novo) 56
  • 13.3 Eli Lilly and Company (India) Pvt. Ltd. (Eli Lilly) 57
  • 13.4 Merck Sharp Dohme India 57
  • 13.5 Abbott India Limited (Abbott India) 58
  • 13.6 Sun Pharmaceutical Industries Limited (Sun Pharma) 59
  • 13.7 USV Limited 60
  • 13.8 Wockhardt Limited (Wockhardt) 61
  • 13.9 Sanofi India Limited 62
  • 13.10 Biocon Limited (Biocon) 63

14 Diabetes Therapeutics Market in India to 2018 - Strategic Consolidations 64

  • 14.1 Introduction 64
  • 14.2 Diabetology Entered into Licensing Agreement with USV for Capsulin on July 31, 2012 64
  • 14.3 Merck Sharp & Dohme Entered into Co-Marketing Agreement with Sun Pharma on April 25, 2011 64
  • 14.4 Eli Lilly and Company (India) Entered into Co-Promotion Agreement with Lupin on July 29, 2011 65
  • 14.5 Sheffield Bio-Science Entered into Collaboration with Wockhardt on February 21, 2011 65
  • 14.6 Eli Lilly Entered into Co-Promotion Agreement with Boehringer Ingelheim for Humalog and Linagliptin on October 3, 2011 65
  • 14.7 Novartis India Entered into Co-Marketing Agreement with USV on December 31, 2008 65
  • 14.8 Pfizer-Biocon Deal Called Off in March 2012 66
    • 14.8.1 Impact Analysis 66

15 Diabetes Therapeutics Market in India to 2018 - Appendix 67

  • 15.1 Market Definitions 67
  • 15.2 Abbreviations 67
  • 15.3 Bibliography 68
  • 15.4 Research Methodology 69
    • 15.4.1 Coverage 69
    • 15.4.2 Secondary Research 70
    • 15.4.3 Primary Research 70
  • 15.5 Therapeutic Landscape 71
    • 15.5.1 Market 73
  • 15.6 Geographical Landscape 74
  • 15.7 Pipeline Analysis 74
  • 15.8 Competitive Landscape 74
    • 15.8.1 Expert Panel Validation 74
  • 15.9 Contact Us 74
  • 15.10 Disclaimer 74

List of Tables

1.1 List of Tables

  • Table 1: Diabetes Market, India, Diagnosis, Blood Sugar Estimation and Interpretation, 2012 14
  • Table 2: Diabetes Market, India, Diagnosis, Oral Glucose Tolerance Test, Estimation and Interpretation (mg/dL), 2012 14
  • Table 3: Diabetes Market, India, Oral Hypoglycemic Agents, Sulfonylurea, 2012 17
  • Table 4: Diabetes Market, India, Oral Hypoglycemic Agents, Thiazolidinediones, 2012 18
  • Table 5: Diabetes Market, India, Oral Hypoglycemic Agents, Biguanides, 2012 19
  • Table 6: Diabetes Market, India, Oral Hypoglycemic Agents, Meglitinides, 2012 20
  • Table 7: Diabetes Market, India, Oral Hypoglycemic Agents, Alpha-glucosidase Inhibitors, 2012 21
  • Table 8: Diabetes Market, India, Treatment Usage Pattern (million), 2004-2011 28
  • Table 9: Diabetes Market, India, Treatment Usage Pattern (million), 2011-2018 28
  • Table 10: Diabetes Market, India, Anti-Diabetic Revenue ($m), 2004-2011 30
  • Table 11: Diabetes Market, India, Anti-Diabetic Revenue Forecast ($m), 2011-2018 30
  • Table 12: Diabetes Market, India, Annual Cost of Therapy ($), 2004-2011 32
  • Table 13: Diabetes Market, India, Annual Cost of Therapy Forecast ($), 2011-2018 32

List of Figures

1.2 List of Figures

  • Figure 1: Diabetes Market, India, Type 2 Diabetes Treatment Model, 2012 15
  • Figure 2: Diabetes Market, Global, Diabetes Prevalence, 2011 25
  • Figure 3: Diabetes Market, Global, Top 10 Diabetes Destinations, 2011 26
  • Figure 4: Diabetes Market, India, Diabetes Population (million), 2011 27
  • Figure 5: Diabetes Market, India, Treatment Usage Pattern (million), 2004-2018 28
  • Figure 6: Diabetes Market, India, Anti-diabetic Revenue Forecast ($m), 2004-2018 30
  • Figure 7: Diabetes Market, India, Annual Cost of Therapy ($), 2004-2018 32
  • Figure 8: Diabetes Market, India, Mean Diabetes-related Expenditure Per Person ($), 2011 33
  • Figure 9: Diabetes Market, India, Drivers and Barriers, 2012 35
  • Figure 10: Diabetes Market, India, Product Pipeline by Phase, 2012 39
  • Figure 11: Diabetes Market, India, Novartis India Limited, Diabetes Product Portfolio, 2012 55
  • Figure 12: Diabetes Market, India, Novo Nordisk, Diabetes Product Portfolio, 2012 56
  • Figure 13: Diabetes Market, India, Eli Lilly, Diabetes Product Portfolio, 2012 57
  • Figure 14: Diabetes Market, India, Merck Sharp Dohme, Diabetes Product Portfolio, 2012 57
  • Figure 15: Diabetes Market, India, Abbott India, Diabetes Product Portfolio, 2012 58
  • Figure 16: Diabetes Market, India, Sun Pharma, Diabetes Product Portfolio, 2012 59
  • Figure 17: Diabetes Market, India, USV Limited, Diabetes Product Portfolio, 2012 60
  • Figure 18: Diabetes Market, India, Wockhardt Limited, Diabetes Product Portfolio, 2012 61
  • Figure 19: Diabetes Market, India, Sanofi, Diabetes Product Portfolio, 2012 62
  • Figure 20: Diabetes Market, India, Biocon Limited, Diabetes Product Portfolio, 2012 63
  • Figure 21: GBI Research Market Forecasting Model 73
Show More
Pricing